It is difficult to treat lung complications caused by chronic graft-versus-host disease (GVHD) after allogeneic stem cell transplantation (allo-SCT). We retrospectively analyzed the characteristics of five patients with mediastinal emphysema (ME) and bilateral pneumothoraces (BP) caused by chronic lung GVHD after allo-SCT. Four of these patients had undergone unrelated SCT, and three had had HLA-identical unrelated donors. All patients received total body irradiation (TBI) during conditioning. Immunosuppressive agents were administered as GHVD prophylaxis, but two patients developed acute GVHD and all the five developed chronic GVHD. The onset of lung complications was 99-1915 days (median, 202 days) after SCT. The onset of ME and BP was 6-48 days (median, 23 days) after the onset of lung complications. Immunosuppressive agents were initially beneficial on the lung complications, but the patients later showed no response to therapy, and all died from respiratory failure 7-195 days (median, 28 days) after the development of ME and BP. The results suggest that these complications progress rapidly, are resistant to treatment, and have a poor prognosis. It is therefore important to start prophylaxis and treatment as early as possible.
occur in patients after allogeneic stem cell transplantation (allo-SCT). [1] [2] [3] These complications are major causes of morbidity and mortality following allo-SCT, and they reduce the quality of life. 4 Infectious and noninfectious lung complications occur during both the early and late phases of the post transplantation period. Bacterial, fungal, and viral infections are mostly seen in the early phase after allo-SCT, 5 and CMV infection [1] [2] [3] [4] [5] and lung complications associated with graft-versus-host disease (GVHD) [6] [7] [8] are frequently seen in the late phase.
IP, BO, and BOOP have been reported as lung complications associated with GVHD, [9] [10] [11] [12] [13] [14] [15] but mediastinal emphysema (ME) and bilateral pneumothoraces (BP) are extremely rare. [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] We reported five cases of ME and BP associated with chronic GVHD.
Patients and methods

Patients
Clinical data for 213 consecutive patients with hematological diseases who had undergone first allo-SCT at Sapporo Hokuyu Hospital between October 1986 and September 2002 were collected and retrospectively analyzed. During this period, 151 patients received chemotherapy and total body irradiation (TBI) as conditioning for allo-SCT. As GVHD prophylaxis, 148 patients received cyclosporin A (CsA) and short-term methotrexate (sMTX), 62 patients had tacrolimus (FK) and sMTX, two patients had CsA only, and one patient was given CsA and prednisolone (PSL). Chronic GVHD occurred in 69 patients. From a review of the data, we found that ME and BP developed in five of these 69 patients.
Only one of these (case 3) had an HLA-identical sibling donor, and the others had undergone unrelated allo-SCT. Case 4 had a one-antigen mismatched donor and case 5 had a two-antigen mismatched donor by HLA DNA typing. Three of these patients received busulfan (BU), cyclophosphamide (CY), and TBI (10 Gy); one received etoposide (VP-16), CY, and TBI (10 Gy); and one received CY, antilymphocyte globulin (ALG), and total lymphoid irradiation (TLI). Immunosuppressive agents were given to all patients after SCT as GVHD prophylaxis. Four patients received CsA and sMTX, and one patient FK506 and sMTX.
Diagnosis of lung complications, ME, and BP by chronic GVHD
Patients were diagnosed as having lung complications on the basis of clinical symptoms and detection of abnormalities on chest X-ray and/or computed tomography (CT) images. [27] [28] [29] Diagnosis of ME and BP with lung chronic GVHD was based on the following criteria: (1) clinical presentation of respiratory symptoms such as cough and dyspnea, and (2) radiological signs of ME and BP, and (3) no evidence of bacterial, viral, fungal or other types of infection.
Results
Five (2.3%) of the 213 patients who had undergone allo-SCT had ME and BP with chronic GVHD. All patients had ME and two also had BP. Clinical data of the five patients with ME and BP are summarized in Table 1 . These were four males and one female aged 15-44 years (median age, 22 years). Only one patient (case 3) had an HLA-identical sibling donor, and the others had undergone unrelated allo-SCT.
Two patients developed acute GVHD (cases 1 and 2). Two patients had acute GVHD (grade 2) of the skin. All patients developed extensive chronic GVHD. Two had the quiescent type, and three had the de novo type.
The onset of lung complications was 99-1915 days (median, 202 days) after allo-SCT. All of the lung complications involved IP. The onset of ME and BP was 6-48 days (median, 23 days) after the occurrence of IP. All of the patients underwent methylprednisolone (mPSL) pulse therapy with or without FK506 for IP, and cases 1 and 3 also received pleural adhesion therapy. Immunosuppressive agents were transiently effective, but all patients later showed resistance to therapy, and all died from respiratory failure 7-195 days (median, 28 days) after the development of ME and BP. Autopsies were performed in cases 1 and 2. Figures 1 and 2 show chest computed tomography (CT) and the pathological findings of cases 1 and 2, respectively. Pathological examination of the lungs showed alveolar destruction and interstitial fibrosis, but no alveolar infiltration by lymphocytes. Table 1 Patient characteristics with mediastinal emphysema (ME) and bilateral pneumothraces (BP) 
Discussion
Chronic GVHD is a late complication of allo-SCT, and involves damage of systemic organs such as the skin, liver, minor salivary glands, mouth, eyes, and musculoskeletal system. [30] [31] [32] In recent years, cases of late-onset lung complications associated with chronic GVHD have been reported. [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] The first detailed report of IP after BMT was a report by Neiman et al in 1973, 6 and an association between IP and allogeneic marrow grafts and GVHD was noted. Yousem 12 recently classified lung GVHD by an integrated assessment of the clinical and pathological features of BMT in patients who had undergone open biopsy. He categorized lung GVHD into four major patterns: (1) diffuse alveolar damage (DAD), (2) lymphocytic bronchitis/bronchiolitis with IP, (3) BOOP, and (4) cicatricial bronchial obstruction. According to this categorization, all of our patients initially showed IP.
On the other hand, ME and BP after allo-SCT are rare complications, [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] and ME and BP with chronic GVHD after allo-SCT are extremely rare, [19] [20] [21] [24] [25] [26] only seven cases having been reported. Characteristics of these cases are summarized in Table 2 . Patients included five males and two females aged 13-43 years (median age, 22 years). Five patients had HLA-identical sibling donors, and two patients had HLA-1 locus-mismatched sibling donors. Various conditioning regimens were used, and only one patient received TBI. Immunosuppressive agents were administered to all patients (apart from one patient whose details are unknown) after allo-SCT as GVHD prophylaxis. Acute GVHD developed in four patients, two of whom had grade 1 and the others grade 2. Extensive chronic GVHD developed in all patients who were treated with steroids. The onset of lung complications was 3-22 months (median, 8 months) after allo-SCT. Lung complications before ME and BP were BO (four patients), IP (two patients), and lung fibrosis (one patient). All except one patient received PSL or other immunosuppressive agents. Surprisingly, four of the seven survived. Our patients differed from those described in the literature reviews in that only one patient in the literature received TBI as part of their conditioning regimen, and all received related bone marrow transplantation. Hill et al 17 reported six cases of ME in allogeneic bone marrow transplant recipients, suggesting that the risk of developing ME increases with an increased total dose of TBI. Moreover, there was a tendency for severe GVHD to occur after allo-SCT from an unrelated donor. 30, 31 We speculate that these factors are associated with an increased risk of ME and BP.
IP occurred in our cases before the development of ME and BP. Idiopathic IP occurs in BMT recipients, and it must be distinguished from CMV pneumonia.
1 CMV pneumonia usually occurs 30-60 days after BMT. However, the IP in our patients occurred 99-1915 days after BMT, without the presence of CMV antigenemia. Idiopathic IP occurs in 10-30% of BMT recipients in the late clinical course and presents as diffuse infiltrates, dyspnea, fever, and hypoxemia. 4, 32 Histological findings in such cases in a recent study were active lymphocytic bronchiolitis with epithelial damage and patchy interstitial mononuclear cell infiltration. 7, 12, 33 These features are associated with chronic GVHD.
With regard to treatment for lung complications due to chronic GVHD, positive responses to CsA and FK506 have been reported. However, the mortality rate in these patients still ranges from 60 to 75%.
11,34-36 Interestingly, two of our patients received pleural adhesion therapy along with immunosuppressive agents. These two patients had longer survival times than did the patients who did not receive pleural adhesion therapy, suggesting that pleural adhesion therapy is effective. In the future, timely pleural adhesion therapy in addition to immunosuppression might improve the outcome. ME and BP in our patients appeared to have developed from IP. These complications cause fibrotic changes in the peripheral airways secondary to repeated inflammatory episodes, thus inducing decreased lung compliance. The mechanism of chronic lung GVHD is not clear. However, it has been suggested that T cells derived from the host cause this damage. 37, 38 Activated CD8 þ T cells, [38] [39] [40] abnormal MHC class 2 antigen expression, 41, 42 and minor histocompatibility antigen expression in the lung tissue as well as increased production of endotoxin may also cause chronic lung GVHD. 43 Therefore, chronic GVHD appears to augment lung injury, resulting in the aggravation of ME and BP.
For early diagnosis of lung complications in asymptomatic patients after allo-SCT, it is necessary to perform noninvasive lung tests, such as capillary blood gas analysis and analysis of oxygen saturation and respiratory function. When patients show clinical signs of lung complications, further diagnostic procedures, including chest radiography and CT, should be performed. Immunosuppressive treatment with PSL, CyA, and FK506 with pleural adhesion therapy is recommended shortly after diagnosis to possibly improve prognosis. FK506 may be preferable for UBMT patients, since this immunosuppressive agent has a stronger inhibitory effect on development of GVHD. 44 In conclusion, we describe five patients with ME, including two patients with both ME and BP, due to chronic GVHD. These complications progressed rapidly and were resistant to treatment. It is therefore important to detect and treat these complications in their early stages.
